Incyte, Novartis Drug Ruxolitinib Fails To Meet Endpoint In Covid-19

Dow Jones

39,806.77

Get Started

Home
Investing
Stocks
UK
LSE
Incyte Corp (0J9P)
Incyte Corp (0J9P) News

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Incyte Corp	LSE:0J9P	London	Ordinary Share		INCYTE ORD SHS

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	66.79						0.00	01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Coml Physical, Biologcl Resh	3.7B	597.6M	2.6666	21.45	12.82B

Incyte, Novartis Drug Ruxolitinib Fails To Meet Endpoint In Covid-19

Incyte Corp and Novartis AG on Monday said a phase 3 study of ruxolitinib in Covid-19 patients failed to meet its pri ...

Subscribe now to see this Premium News article from

Alliance News Professional covers every UK stock in your portfolio. It goes beyond regulatory news and free web services to give your investment decisions an edge over the crowd.

Click for a FREE Trial

In The Know - Management and analyst comments that go beyond company announcements.
Flash headlines on all 2,400 London-listed companies before the news hits the open web.
Broker Ratings - The earliest tip-offs, many before the market opens.
Economic data and central bank flashes from UK, US and eurozone.
Taking AIM - Up to the minute market commentary on AIM stocks.
Over 500 news items per trading day for just £39.60 per month, and cancel at any time.

Try Alliance News FREE for 1 Month

Call us on +44 (0) 203 8794 460 to get started.